<DOC>
	<DOCNO>NCT00721812</DOCNO>
	<brief_summary>A First-Time-in-Human Study Evaluate Safety , Tolerability Pharmacokinetics GSK1399686 After Single Repeated Oral Dosing Healthy Volunteers</brief_summary>
	<brief_title>A First Time In Human Study Evaluate Safety , Tolerability Pharmacokinetics GSK1399686</brief_title>
	<detailed_description />
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Inclusion criterion : Healthy determine responsible physician Male , RDF cohort female nonchildbearing potential , 18 65 year age . Body weight great 50 kg ( 110 lb ) BMI within range 18.529.9 kg/m2 ( inclusive ) . QTcB QTcF &lt; 450 msec Capable give write informed consent Exclusion criterion : The subject positive prestudy drug/alcohol screen History regular alcohol consumption within 6 month study define average weekly intake great 21 unit Urinary cotinine level indicative active smoking regular use tobacco A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody A positive test HIV antibody The subject participate clinical trial receive investigational product within 30 day , 5 halflives investigational product Exposure four new chemical entity within 12 month Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juice within 7 day Subject receive hormone replacement therapy History sensitivity study medication History sensitivity heparin heparininduced thrombocytopenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>IBD</keyword>
	<keyword>first time human</keyword>
	<keyword>Phase 1</keyword>
	<keyword>human volunteer</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>